CL2017001595A1 - Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas - Google Patents
Composiciones de vacuna para el virus del dengue y métodos de uso de las mismasInfo
- Publication number
- CL2017001595A1 CL2017001595A1 CL2017001595A CL2017001595A CL2017001595A1 CL 2017001595 A1 CL2017001595 A1 CL 2017001595A1 CL 2017001595 A CL2017001595 A CL 2017001595A CL 2017001595 A CL2017001595 A CL 2017001595A CL 2017001595 A1 CL2017001595 A1 CL 2017001595A1
- Authority
- CL
- Chile
- Prior art keywords
- dengue
- vaccine
- virus
- vaccine compositions
- compositions
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 12
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 241000725619 Dengue virus Species 0.000 title 1
- 208000001490 Dengue Diseases 0.000 abstract 11
- 206010012310 Dengue fever Diseases 0.000 abstract 11
- 208000025729 dengue disease Diseases 0.000 abstract 11
- 241000700605 Viruses Species 0.000 abstract 4
- 241000710829 Dengue virus group Species 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095331P | 2014-12-22 | 2014-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001595A1 true CL2017001595A1 (es) | 2018-01-26 |
Family
ID=56151628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001595A CL2017001595A1 (es) | 2014-12-22 | 2017-06-16 | Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10449243B2 (enExample) |
| EP (1) | EP3236997B1 (enExample) |
| JP (1) | JP2018502080A (enExample) |
| CN (1) | CN106999568A (enExample) |
| AU (1) | AU2015369875A1 (enExample) |
| BR (1) | BR112017013270A2 (enExample) |
| CL (1) | CL2017001595A1 (enExample) |
| CO (1) | CO2017005830A2 (enExample) |
| CR (1) | CR20170280A (enExample) |
| ES (1) | ES2981476T3 (enExample) |
| MX (1) | MX383329B (enExample) |
| MY (1) | MY192543A (enExample) |
| NI (1) | NI201700080A (enExample) |
| PH (1) | PH12017501165B1 (enExample) |
| SG (1) | SG11201704942QA (enExample) |
| WO (1) | WO2016106107A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170143817A1 (en) * | 2015-11-20 | 2017-05-25 | Oregon Health & Science University | Dengue virus vaccine |
| TWI625393B (zh) * | 2016-11-15 | 2018-06-01 | 國立清華大學 | 對抗複數種登革熱病毒血清型之疫苗套組及其製備方法與用途 |
| IL316312A (en) | 2017-12-07 | 2024-12-01 | Merck Sharp ַ& Dohme Llc | Dengue virus vaccine compound formulations |
| US11433129B2 (en) * | 2019-05-20 | 2022-09-06 | Soligenix, Inc. | Compositions and methods of manufacturing trivalent filovirus vaccines |
| WO2025027616A1 (en) * | 2023-08-01 | 2025-02-06 | Serum Institute Of India Private Limited | Freeze-dried viral vaccine compositions and method of manufacturing thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| US6254873B1 (en) | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
| US6190859B1 (en) | 1995-04-17 | 2001-02-20 | The United States Of America As Represented By The Secretary Of The Army | Method and kit for detection of dengue virus |
| WO1996040933A1 (en) | 1995-06-07 | 1996-12-19 | The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| EP0836090A1 (en) | 1996-10-12 | 1998-04-15 | Evotec BioSystems GmbH | Method of analysis of samples by determination of the distribution of specific brightnesses of particles |
| ES2345614T3 (es) | 1997-02-28 | 2010-09-28 | Sanofi Pasteur Biologics Co. | Vacunas quimericas de flavivirus. |
| KR20010022452A (ko) | 1997-07-31 | 2001-03-15 | 추후제출 | 플라비바이러스 감염에 대한 재조합 다이머형 엔벨롭 백신 |
| WO2000014245A1 (en) | 1998-09-02 | 2000-03-16 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Dengue viruses that are replication defective in mosquitos for use as vaccines |
| AU779280B2 (en) | 1999-03-26 | 2005-01-13 | Walter Reed Army Institute Of Research | Multivalent dengue virus vaccine |
| WO2000057909A2 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-2 virus vaccine |
| JP2002540169A (ja) | 1999-03-26 | 2002-11-26 | ウォルター リード アーミー インスティテュート オブ リサーチ | 弱毒化デング熱１型ウイルスワクチン |
| US6537557B1 (en) | 1999-03-26 | 2003-03-25 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-4 virus vaccine |
| US6432411B1 (en) | 1999-07-13 | 2002-08-13 | Hawaii Biotechnology Group | Recombinant envelope vaccine against flavivirus infection |
| CA2755964C (en) | 2001-05-22 | 2017-06-27 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| JP2005519639A (ja) | 2002-01-15 | 2005-07-07 | アカンビス インコーポレーティッド | フラビウイルスワクチン |
| ES2355719T3 (es) | 2002-05-03 | 2011-03-30 | The United States Government As Represented By The Department Of Health And Human Services | Vacuna contra el dengue que contiene una deleción común de 30 nucleótidos en la utr en 3' del dengue tipos 1 y 2. |
| AU2003239932A1 (en) | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| US7189403B2 (en) | 2003-06-30 | 2007-03-13 | Institut Pasteur | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications |
| KR101138131B1 (ko) | 2003-12-08 | 2012-04-23 | 이데라 파마슈티칼즈, 인코포레이티드 | 작은 올리고뉴클레오티드-기초 화합물에 의한 면역자극특성의 조절 |
| SG156666A1 (en) | 2004-10-20 | 2009-11-26 | Acambis Inc | Vaccines against japanese encephalitis virus and west nile virus |
| WO2006134433A1 (en) | 2005-06-17 | 2006-12-21 | Sanofi Pasteur | Dengue serotype 1 attenuated strain |
| DE602006015807D1 (de) | 2005-06-17 | 2010-09-09 | Ct S For Disease Control & Pre | Abgeschwächter dengue-serotyp-2-stamm |
| EP1896069B1 (en) | 2005-06-24 | 2013-03-13 | Intervet International BV | Inactivated chimeric vaccines and related methods of use |
| WO2007015783A2 (en) | 2005-07-22 | 2007-02-08 | Research Development Foundation | Attenuated strains of flaviviruses , and uses thereof |
| US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| AR061197A1 (es) | 2006-06-07 | 2008-08-13 | Sanofi Pasteur | Cepas del virus 3 del dengue vivas atenuadas |
| DK2054428T3 (da) | 2006-08-15 | 2013-08-26 | Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea | Udvikling af bestanddele til denque-virus-vaccine |
| FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| WO2008127307A2 (en) | 2006-11-09 | 2008-10-23 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using prime-boost approach |
| US8440202B2 (en) | 2006-11-09 | 2013-05-14 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using the prime-boost approach |
| BRPI0904020B8 (pt) | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | composição vacinal contra o vírus da dengue, e, kit |
| BR112013009649A2 (pt) * | 2010-10-29 | 2016-07-12 | Merck Sharp & Dohme | composição imunogênica, métodos para provocar uma resposta imune protetora em um paciente humano e para fornecer proteção imune em seres humanos contra doença, e, uso de uma composição |
| US20120294889A1 (en) * | 2010-11-12 | 2012-11-22 | Paxvax, Inc. | Chimeric Flavivirus Vaccines |
| US20150265695A1 (en) * | 2012-07-24 | 2015-09-24 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
| EP3010536A4 (en) | 2013-06-21 | 2016-11-30 | Merck Sharp & Dohme | DENGUE VIRUS VACCINE COMPOSITIONS AND METHODS FOR USE THEREOF |
-
2015
- 2015-12-18 AU AU2015369875A patent/AU2015369875A1/en not_active Abandoned
- 2015-12-18 JP JP2017533387A patent/JP2018502080A/ja active Pending
- 2015-12-18 CN CN201580070223.8A patent/CN106999568A/zh active Pending
- 2015-12-18 MX MX2017008342A patent/MX383329B/es unknown
- 2015-12-18 EP EP15874179.3A patent/EP3236997B1/en active Active
- 2015-12-18 BR BR112017013270A patent/BR112017013270A2/pt not_active Application Discontinuation
- 2015-12-18 US US15/536,319 patent/US10449243B2/en active Active
- 2015-12-18 CR CR20170280A patent/CR20170280A/es unknown
- 2015-12-18 PH PH1/2017/501165A patent/PH12017501165B1/en unknown
- 2015-12-18 WO PCT/US2015/066549 patent/WO2016106107A2/en not_active Ceased
- 2015-12-18 SG SG11201704942QA patent/SG11201704942QA/en unknown
- 2015-12-18 MY MYPI2017000917A patent/MY192543A/en unknown
- 2015-12-18 ES ES15874179T patent/ES2981476T3/es active Active
-
2017
- 2017-06-14 CO CONC2017/0005830A patent/CO2017005830A2/es unknown
- 2017-06-16 CL CL2017001595A patent/CL2017001595A1/es unknown
- 2017-06-20 NI NI201700080A patent/NI201700080A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015369875A1 (en) | 2017-06-15 |
| EP3236997A2 (en) | 2017-11-01 |
| ES2981476T3 (es) | 2024-10-09 |
| WO2016106107A2 (en) | 2016-06-30 |
| MX2017008342A (es) | 2017-10-24 |
| CR20170280A (es) | 2017-08-21 |
| CO2017005830A2 (es) | 2017-08-31 |
| SG11201704942QA (en) | 2017-07-28 |
| WO2016106107A3 (en) | 2016-08-18 |
| CN106999568A (zh) | 2017-08-01 |
| NI201700080A (es) | 2017-07-18 |
| PH12017501165A1 (en) | 2017-12-11 |
| EP3236997B1 (en) | 2024-05-29 |
| US20170360917A1 (en) | 2017-12-21 |
| PH12017501165B1 (en) | 2023-02-22 |
| MY192543A (en) | 2022-08-26 |
| BR112017013270A2 (pt) | 2018-03-06 |
| MX383329B (es) | 2025-03-13 |
| EP3236997A4 (en) | 2018-05-30 |
| JP2018502080A (ja) | 2018-01-25 |
| US10449243B2 (en) | 2019-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001433A1 (es) | Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684) | |
| CL2022001719A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
| MX2023013140A (es) | Vacunas contra el virus de la hepatitis b. | |
| CL2016002179A1 (es) | Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b. | |
| UY32457A (es) | Vacuna del virus del dengue inactivado | |
| BR112017008868A2 (pt) | composições de irna do vírus da hepatite b (hbv) e métodos de seu uso | |
| MX373884B (es) | Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta. | |
| EA201890454A1 (ru) | Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств | |
| EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
| MX2017003117A (es) | Particula tipo virus de flavivirus. | |
| BR112019006802A2 (pt) | compostos e métodos para diagnóstico e tratamento de infecções virais | |
| MX2017011655A (es) | Compuestos de aza-piridona y usos de estos. | |
| CR20160178A (es) | Derivados de desoxinojirimicina y sus métodos de uso | |
| BR112015031226A2 (pt) | Composição de vacina, e, uso da composição de vacina | |
| CL2018001946A1 (es) | Virus atenuados de bronquitis infecciosa. | |
| CO2017005830A2 (es) | Composiciones de vacuna para el virus del dengue | |
| CO7461135A2 (es) | Parvovirus porcino 5b, métodos de uso y vacuna | |
| PH12017501100A1 (en) | Recombinant swinepox virus and vaccines | |
| EA201790771A1 (ru) | Фармацевтические композиции длительного действия для лечения гепатита c | |
| EA201790776A1 (ru) | Комбинированные композиции длительного действия и способы лечения гепатита с | |
| AR095118A1 (es) | Un procedimiento de inactivación viral en composición que comprende factor vii | |
| EA202090236A1 (ru) | Иммуногенные композиции senecavirus a и способы с ними | |
| BR112018069193A2 (pt) | uma vacina de combinação contra infecção por vírus pcv2 e prrs compreendendo albumina | |
| MX2019000645A (es) | Uso de xibornol como agente activo en el tratamiento de infecciones virales. | |
| EA201892488A1 (ru) | Комбинации лечебных вакцин против впч |